ANN ARBOR, Mich., March 24, 2025 — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk biotechnology, today announced a groundbreaking scientific achievement in the development of high-performance biomaterials. Kraig Labs successfully engineered the largest known spider silk gene insert into silkworm—nearly doubling the previous record. This breakthrough represents a major step toward creating next-generation spider silk fibers with enhanced strength, flexibility, and performance potential.

The project was led by Dr. Xiaoli Zhang, the Company’s research manager, whose team continues to push the boundaries of genetic engineering for spider silk production.

“This milestone significantly expands the possibilities for spider silk technology,” said Dr. Zhang. “By increasing the size of the inserted spider silk genes, we are unlocking the potential for new materials with properties beyond what is currently achievable. This breakthrough lays the foundation for the future of high-performance silk fibers.”

While the sheer size of the genetic insert marks a scientific breakthrough, its real significance is not in its size but in the information this genetic packet carries. This allows for the creation of larger more complex proteins with unique mechanical properties for incorporation into the silk fibers. As Kraig Labs moves forward with this technology, the Company will explore the tremendous opportunities for increases in material performance these new larger packets allow.

This scientific accomplishment represents a bold step forward in material innovation and expands the possibilities of what can be achieved in material performance. Kraig Labs remains fully committed to the commercialization of its current recombinant spider silk production strains, even as it accelerates its development of more advanced materials. The Company is moving forward rapidly to advance the scale-up of its existing technologies, bringing spider silk fibers to market for applications in performance textiles, defense, and industrial sectors.

“Our mission is twofold: to commercialize our existing spider silk technology while continuously innovating for the future,” said Company CEO and founder, Kim Thompson. “This record-setting genetic achievement underscores the depth of our research capabilities and demonstrates our long-term vision for creating even more advanced biomaterials. Dr. Zhang and her team have taken a critical step toward making the next generation of spider silk a reality.”

Kraig Labs is currently accelerating its recombinant spider silk production, while also investing in the future of spider silk technology. The Company will continue to provide updates on both its commercialization efforts and its groundbreaking research.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., March 17, 2025 — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs“), a world leader in spider silk manufacturing, is pleased to confirm it has established production operations in Lam Dong Province, Vietnam. This milestone marks the fulfillment of a long-standing strategic goal that the Company has pursued for more than a decade.

In January of this year, Kraig Labs announced the issuance of a new Investment Registration Certificate (IRC) for expanded production. This IRC was a critical regulatory achievement, paving the way for the Company to fully establish and scale its production in Vietnam’s premier silk-producing region.

As the heart of Vietnam’s silk production, Lam Dong Province is the ideal location for the Company’s expansion and investment into large-scale spider silk manufacturing. With the recently issued report by the Department of Finance in Lam Dong, Kraig Labs can now officially confirm its presence in the region.

With this key development, Kraig Labs is accelerating its production growth, positioning the Company to execute its ambitious expansion plans for 2025 and beyond. By establishing operations in Vietnam’s silk capital, the Company is strengthening its supply chain and scaling up its proprietary spider silk production.

“This is a transformative moment for Kraig Biocraft Laboratories,” said the Company’s Founder and CEO, Kim Thompson. “Establishing operations in Lam Dong has been a priority for more than ten years and now, with our footprint firmly in place, we are making significant investments to drive our production to unprecedented levels.”

As Kraig Labs continues to expand, the Company remains committed to leveraging its innovative technology to revolutionize the performance textiles industry while contributing to the development of Vietnam’s silk sector.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., March 10, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a global leader in engineered spider silk technologies, is thrilled to announce that it has begun production of the largest single batch of BAM-1 recombinant spider silk in the Company’s history. Last year, the Company publicly set a goal of exceeding all of 2024’s production with a single production batch in 2025. Today, Kraig Labs announces it has far exceeded that goal and kept that promise.

In 2024, Kraig Labs produced more spider silk than in all previous years combined. Following a record-breaking 2024, the Company is now surpassing that milestone with just a single production run in early 2025. This single production run is larger than the Company’s entire output for the previous 12 months. This extraordinary expansion underscores the Company’s continued success in scaling up the commercial production of its revolutionary spider silk technology.

“Today, we are making history,” said Jon Rice, Chief Operations Officer of Kraig Labs. “This production run is not just our largest to date—it is larger than everything we produced throughout all of 2024. This achievement demonstrates our ability to dramatically scale BAM-1 silk output, bringing us closer than ever to meeting what we see as an immense global demand for high-performance spider silk.”

The current BAM-1 silk production run is the latest in a series of breakthroughs that validate the Company’s robust spider silk production platform and its ability to deliver industrial-scale quantities of its cutting-edge biomaterial. Kraig Labs remains committed to pushing the boundaries of advanced material science, leveraging its scalable production systems to create unprecedented opportunities in technical textiles, defense, and performance apparel industries.

“As we continue to ramp up production, this milestone is a clear testament to the dedication of our team and the scalability of our technology,” said Rice. “We set out to revolutionize the performance materials market, and we are proving that spider silk is no longer a material of the future—it is here today and ready for commercialization.”

With this historic production milestone, Kraig Labs is further solidifying its position as the industry leader in spider silk manufacturing. The Company looks forward to sharing further updates as it advances toward commercial deliveries and strategic partnerships.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Paving the Way for Advanced Material Performance

ANN ARBOR, Mich., February 26, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Kraig Labs” or “the Company”), a leading developer of spider silk-based fibers, today announced a significant breakthrough in its genetic research program. The Company’s research team has successfully doubled the complexity and size of its spider silk gene insert package; a milestone expected to drive new advancements in material performance.

Building on its pioneering work in recombinant spider silk production, the Company’s latest achievement represents a major step forward in the development of next-generation fibers. By expanding the gene insert package, Kraig Labs aims to create more advanced silk materials with improved strength, elasticity, and durability—critical attributes for high-performance applications in technical textiles, defense, and medical industries.

“We believe that larger and more complex gene insert packages hold the potential to unlock superior material characteristics in our spider silk fibers,” said Kim Thompson, CEO and Founder of Kraig Labs. “This breakthrough reinforces our leadership in biomaterials innovation and sets the stage for the next evolution of spider silk technology.”

While this cutting-edge research progresses in the lab, Kraig Labs remains committed to bringing its revolutionary spider silk fibers to market. The Company’s production team continues its focus on commercial-scale spider silk manufacturing, with targeted material sales into multiple markets. Kraig Labs expects this will be a pivotal year for industry integration of spider silk.

“Our production team is on track to deliver commercial quantities of our spider silk this year, even as our research team pushes the boundaries of what’s possible in the lab,” added the Company’s COO, Jon Rice. “We are strategically balancing innovation and production to meet the growing demand for our game-changing materials.”

With its dual focus on both research and commercialization, Kraig Labs is solidifying its position as a global leader in spider silk technology. The Company remains dedicated to transforming the future of performance materials with bioengineered spider silk.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com